Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors

Background: Recently published data show some controversy concerning the impact of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in predicting head and neck tumors (HNT) outcome. Assessment of tumor blood supply parameters using dynamic contrast-enhanced CT (DCE-CT) may deliver additional information concerning this important question. Purpose: To evaluate the contribution of DCE-CT implemented in pretherapeutic FDG-PET/CT protocol for prognosis prediction in patients with HNT. Material and Methods: Ten consecutive patients (median age 50 years, range 47–74 years) with histologically proven HNT underwent FDG-PET/CT with DCE-CT before treatment. FDG uptake was measured by maximum standardized uptake value (SUVmax). Relative tumor blood volume (rTBV) was determined from DCE-CT using Patlak analysis. Intratumoral heterogeneity was assessed by means of lacunarity analysis. Obtained values were compared with time-to-progression and overall survival. PET and DCE-CT images were compared on a pixel-by-pixel basis using Pearson coefficient of correlation. Results: Three patients with lower FDG uptake (SUVmax: 8±1) and five patients with higher FDG uptake (SUVmax: 15±4, P=0.004) were free of local recurrence for 24 months. Two groups of patients with significantly differing lower (group A: 0.37±0.02, n=6) and higher (group B: 0.52±0.01, n=4; P<0.01), tumor heterogeneity (lacunarity) were identified. Corresponding mean rTBV was higher in group A (9.6±1.8 ml/100 ml) than in group B (6.2±0.6 ml/100 ml). All six patients with homogeneous tumor blood supply (lower lacunarity) and higher rTBV were free of local recurrence during 24 months, while two of four patients with heterogeneous tumor blood supply (higher lacunarity) and lower rTBV died during follow-up due to tumor relapse. A weak correlation between FDG-PET and DCE-CT rTBV was observed (R2=0.1). Conclusion: FDG-PET/CT and DCT-CT are complementary methods for surveillance assessment in patients with HNT. Implementation of DCE-CT in the pretreatment FDG-PET/CT protocol may improve tumor outcome prediction.

[1]  Aditya Bansal,et al.  Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. , 2006, Nuclear medicine and biology.

[2]  S. Mukherji,et al.  Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? , 2007, AJNR. American journal of neuroradiology.

[3]  Nasreddin Abolmaali,et al.  Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  S. Rockwell,et al.  Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. , 1984, International journal of radiation oncology, biology, physics.

[5]  J. Roh,et al.  2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  J Martin Brown,et al.  Tumor Microenvironment and the Response to Anticancer Therapy , 2002, Cancer biology & therapy.

[7]  Lale Kostakoglu,et al.  PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  F. De Conno,et al.  for anticancer therapy , 2022 .

[9]  Peter Bartenstein,et al.  Overexpression of Glut‐1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma , 2003, Cancer.

[10]  Zoran Rumboldt,et al.  Perfusion CT for head and neck tumors: pilot study. , 2005, AJNR. American journal of neuroradiology.

[11]  Z. Rumboldt,et al.  Whole-Tumor Perfusion CT Parameters and Glucose Metabolism Measurements in Head and Neck Squamous Cell Carcinomas: A Pilot Study Using Combined Positron-Emission Tomography/CT Imaging , 2008, American Journal of Neuroradiology.

[12]  J. Steinbach,et al.  Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  W. Oyen,et al.  Biological correlates of FDG uptake in non-small cell lung cancer. , 2007, Lung cancer.

[14]  J. Roh,et al.  Use of 18F-FDG PET for Primary Treatment Strategy in Patients with Squamous Cell Carcinoma of the Oropharynx , 2007, Journal of Nuclear Medicine.

[15]  D. Burk,et al.  On respiratory impairment in cancer cells. , 1956, Science.

[16]  W. Hargrove,et al.  Lacunarity analysis: A general technique for the analysis of spatial patterns. , 1996, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[17]  Keith M. Stantz,et al.  Response to Letter Regarding Article: "Developing DCE-CT to Quantify Intra-Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype" , 2010, IEEE Trans. Medical Imaging.

[18]  Martin Utley,et al.  FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. , 2007, Lung cancer.

[19]  Mohamed Allaoua,et al.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. , 2004, International journal of radiation oncology, biology, physics.

[20]  W. B. Marks,et al.  Fractal methods and results in cellular morphology — dimensions, lacunarity and multifractals , 1996, Journal of Neuroscience Methods.

[21]  K. Miles,et al.  Blood flow–metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Daniela Thorwarth,et al.  Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Peter Vaupel,et al.  Tumor microenvironmental physiology and its implications for radiation oncology. , 2004, Seminars in radiation oncology.

[24]  Keith M. Stantz,et al.  Developing DCE-CT to Quantify Intra-Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype , 2009, IEEE Transactions on Medical Imaging.

[25]  H. Ishikura,et al.  Pathophysiology of Tumor Neovascularization , 2005, Vascular health and risk management.

[26]  A. Kuten,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management. , 2007, International journal of radiation oncology, biology, physics.

[27]  Philippe Lambin,et al.  Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[28]  Volker Hietschold,et al.  Comment on "Developing DCE-CT to Quantify Intra-Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype , 2009 .

[29]  P. Vaupel,et al.  Tumor blood flow: The principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo , 1989, International journal of cancer.

[30]  Z. Keidar,et al.  The Role of FDG-PET/CT Imaging in Head and Neck Malignant Conditions: Impact on Diagnostic Accuracy and Patient Care , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[31]  M. Eble,et al.  [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study , 2006, BMC Cancer.

[32]  M. Leblanc,et al.  FDG-PET prediction of head and neck squamous cell cancer outcomes. , 2004, Archives of otolaryngology--head & neck surgery.

[33]  D. Wood,et al.  Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role , 2007, Clinical Cancer Research.

[34]  P. Lambin,et al.  Oxygenation of head and neck tumors , 1993, Cancer.

[35]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Kuten,et al.  Fluorodeoxyglucose‐Positron Emission Tomography/Computed Tomography Imaging in Patients with Carcinoma of the Larynx: Diagnostic Accuracy and Impact on Clinical Management , 2006, The Laryngoscope.

[37]  Y. Ouchi,et al.  Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. , 2009, AJR. American journal of roentgenology.